Tuberous sclerosis is a rare genetic condition caused byTSC1orTSC2mutations that can be inherited, sporadic, or the result of somatic mosaicism. Subependymal giant-cell astrocytoma (SEGA) is a major diagnostic feature of tuberous sclerosis complex (TSC). This study aimed to present a series of cases in which a pathological diagnosis of SEGA was not diagnostic of tuberous sclerosis.
The authors retrospectively reviewed a clinical case series of 5 children who presented with a SEGA tumor to Johns Hopkins All Children’s Hospital and St. Louis Children’s Hospital between 2010 and 2022 and whose initial genetic workup was negative for tuberous sclerosis. All patients were treated with craniotomy for SEGA resection.TSCgenetic testing was performed on all SEGA specimens.
The children underwent open frontal craniotomy for SEGA resection from the ages of 10 months to 14 years. All cases demonstrated the classic imaging features of SEGA. Four were centered at the foramen of Monro and 1 in the occipital horn. One patient presented with hydrocephalus, 1 with headaches, 1 with hand weakness, 1 with seizures, and 1 with tumor hemorrhage. SomaticTSC1mutation was present in the SEGA tumors of 2 patients andTSC2mutation in 1 patient. Germline TSC mutation testing was negative for all 5 cases. No patient had other systemic findings of tuberous sclerosis on ophthalmological, dermatological, neurological, renal, or cardiopulmonary assessments and thus did not meet the clinical criteria for tuberous sclerosis. The average follow-up was 6.7 years. Recurrence was noted in 2 cases, in which 1 patient underwent radiosurgery and 1 was started on a mammalian target of rapamycin (mTOR) inhibitor (rapamycin).
There may be intracranial implications of somatic mosaicism associated with tuberous sclerosis. Children who are diagnosed with SEGA do not necessarily have a diagnosis of tuberous sclerosis. Tumors may carry aTSC1orTSC2mutation, but germline testing can be negative. These children should continue to be followed with serial cranial imaging for tumor progression, but they may not require the same long-term monitoring as patients who are diagnosed with germlineTSC1orTSC2mutations.
INCLUDE WHEN CITINGPublished online June 9, 2023; DOI: 10.3171/2023.5.PEDS23108.
DisclosuresDr. Smyth reported personal fees from Monteris Medical and Zimmer Biomet ROSA outside the submitted work.
HenskeEP,JóźwiakS,KingswoodJC,SampsonJR,ThieleEA.Tuberous sclerosis complex.Nat Rev Dis Primers.2016;2:16035.
GrajkowskaW,KotulskaK,JurkiewiczE,MatyjaE.Brain lesions in tuberous sclerosis complex.Folia Neuropathol.2010;48(3):139–149.
NorthrupH,KruegerDA.Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference.Pediatr Neurol.2013;49(4):243–254.
NorthrupH,AronowME,BebinEM,et al.更新国际结节性硬化症复杂Diagnostic Criteria and Surveillance and Management Recommendations.Pediatr Neurol.2021;123:50–66.
van SlegtenhorstM,de HoogtR,HermansC,et al.Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34.Science.1997;277(5327):805–808.
LamHC,NijmehJ,HenskeEP.New developments in the genetics and pathogenesis of tumours in tuberous sclerosis complex.J Pathol.2017;241(2):219–225.
European Chromosome 16 Tuberous Sclerosis Consortium.Identification and characterization of the tuberous sclerosis gene on chromosome 16.Cell.1993;75(7):1305–1315.
TyburczyME,DiesKA,GlassJ,et al.镶嵌在TSC和intronic突变1/TSC2 explain the majority of TSC patients with no mutation identified by conventional testing.PLoS Genet.2015;11(11):e1005637.
D’GamaAM,WalshCA.Somatic mosaicism and neurodevelopmental disease.Nat Neurosci.2018;21(11):1504–1514.
Manzanilla-RomeroHH,WeisD,SchnaiterS,Rudnik-SchönebornS.Low-level mosaicism in tuberous sclerosis complex in four unrelated patients: comparison of clinical characteristics and diagnostic pathways.Am J Med Genet A.2021;185(12):3851–3858.
AltermattHJ,ScheithauerBW.Cytomorphology of subependymal giant cell astrocytoma.Acta Cytol.1992;36(2):171–175.
BuccolieroAM,FranchiA,CastiglioneF,et al.Subependymal giant cell astrocytoma (SEGA): Is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study.Neuropathology.2009;29(1):25–30.
FohlenM,HarzallahI,PolivkaM,et al.Identification of TSC1 or TSC2 mutation limited to the tumor in three cases of solitary subependymal giant cell astrocytoma using next-generation sequencing technology.Childs Nerv Syst.2020;36(5):961–965.
HallA,WestlakeG,ShortBP,PearsonM,EssKC.TSC1 mosaicism leading to subependymal giant cell astrocytoma but not tuberous sclerosis complex.Pediatr Neurol.2021;123:38–39.
KhanM,GuzmanMA,TaniosA.Story of the solitary subependymal giant cell astrocytoma: a case report and literature review.Clin Neuropathol.2022;41(1):6–11.
O’RaweM,ChandranAS,JoshiS,SimoninA,DykeJM,LeeS.A case of subependymal giant cell astrocytoma without tuberous sclerosis complex and review of the literature.Childs Nerv Syst.2021;37(4):1381–1385.
SuzukiM,KondoA,OginoI,et al.A case of solitary subependymal giant cell astrocytoma with histopathological anaplasia and TSC2 gene alteration.Childs Nerv Syst.2021;37(4):1357–1362.
IchikawaT,WakisakaA,DaidoS,et al.A case of solitary subependymal giant cell astrocytoma: two somatic hits of TSC2 in the tumor, without evidence of somatic mosaicism.J Mol Diagn.2005;7(4):544–549.
SasakiT,UdaT,KukiI,et al.TSC2 somatic mosaic mutation, including extra-tumor tissue, may be the developmental cause of solitary subependymal giant cell astrocytoma.Childs Nerv Syst.2022;38(1):77–83.
TompeAP,SargarKM,KazmiSAJ,ShimonyN.A solitary extraventricular subependymal giant cell astrocytoma in the absence of tuberous sclerosis.Radiol Case Rep.2021;16(1):180–184.
KwiatkowskiDJ,WhittemoreVH,ThieleEA, eds.Tuberous Sclerosis Complex: Genes, Clinical Features and Therapeutics.John Wiley & Sons;2011.
TengJM,CowenEW,Wataya-KanedaM,et al.Dermatologic and dental aspects of the 2012 International Tuberous Sclerosis Complex Consensus Statements.JAMA Dermatol.2014;150(10):1095–1101.
CotterJA.An update on the central nervous system manifestations of tuberous sclerosis complex.Acta Neuropathol.2020;139(4):613–624.
ArroyoMS,KruegerDA,BroomallE,StevensonCB,FranzDN.Acute management of symptomatic subependymal giant cell astrocytoma with everolimus.Pediatr Neurol.2017;72:81–85.
BobeffK,KrajewskaK,BaranskaD,et al.Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis - final results from the EMINENTS study.Front Neurol.2021;12:581102.
JóźwiakS,KotulskaK,BerkowitzN,BrechenmacherT,FranzDN.Safety of everolimus in patients younger than 3 years of age: results from EXIST-1, a randomized, controlled clinical trial.J Pediatr.2016;172:151–155.e1.
DadeyDY,KamathAA,LeuthardtEC,SmythMD.Laser interstitial thermal therapy for subependymal giant cell astrocytoma: technical case report.Neurosurg Focus.2016;41(4):E9.
KarsyM,PatelDM,BolloRJ.Trapped ventricle after laser ablation of a subependymal giant cell astrocytoma complicated by intraventricular gadolinium extravasation: case report.J Neurosurg Pediatr.2018;21(5):523–527.
WeidmanDR,PalasamudramS,ZakM,et al.The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).J Neurooncol.2020;147(3):731–736.
AlmubarakAO,AbdullahJ,Al HindiH,AlShailE.Infantile atypical subependymal giant cell astrocytoma.Neurosciences (Riyadh).2020;25(1):61–64.
All Time | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 626 | 626 | 110 |
Full Text Views | 100 | 100 | 14 |
PDF Downloads | 100 | 100 | 20 |
EPUB Downloads | 0 | 0 | 0 |